Skip to main content
Hit enter to search or ESC to close
Close Search
Menu
Company
Team
Psybrary™
Pipeline
Investors
Investor Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts
Contact
twitter
facebook
linkedin
Investors
Media Coverage
NASDAQ: ENVB
Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts
Media Coverage
Aligning financial plans to long-term goals [The CFO]
October 19, 2023
Has British biotech outgrown the Square Mile? [Proactive]
October 5, 2023
Biotech firm receives patent for psilocybin-derived mental health therapeutics [Helio]
October 2, 2023
Psilocybin-Based Drug Candidate Gains Patent [High Times]
October 2, 2023
U.S. approval for psychedelic drug MDMA nears after success in clinic [Labiotech]
September 22, 2023
Enveric Biosciences Nabs U.S. Patent For Novel Psilocybin Derivatives, Details Here [Benzinga]
September 22, 2023
Enveric Receives Patent For Psilocybin Molecules [Green Market Report]
September 20, 2023
NASDAQ-Listed Enveric To Split Into Two Companies, One For Cannabinoids, One For Psychedelics
May 11, 2022
Enveric Offers Investors Rare Exposure To Both Cannabis And Psychedelic Industries [Benzinga]
April 19, 2022
Bob Dagher, Chief Medical Officer at Enveric Biosciences [The Green Rush]
March 31, 2022
‹
1
2
3
4
5
…
9
›
Close Menu
Company
Team
Psybrary™
Pipeline
Investors
Investor Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts
Contact